[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Microsphere Agents Market in China 2021

March 2021 | 21 pages | ID: MCEE87750FEFEN
StrategyHelix Inc

US$ 450.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The microsphere agents market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.3% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for microsphere agents. The China microsphere agents market is segmented on the basis of type. By type, it is categorized into Leuprorelin, Triptorelin, and others. The Leuprorelin segment held the largest market share in 2020.

The report has profiled some of the key players of the market such as Beijing Biote Pharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Takeda Pharmaceutical Company Limited.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the microsphere agents market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope
Type: Leuprorelin, Triptorelin, and others
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the China microsphere agents market
Pinpoint growth sectors and trends for investment
Understand what the future of the microsphere agents market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. MARKET DATA & OUTLOOK

3.1 Market Value
3.2 Market Value Forecast

4. MICROSPHERE AGENTS MARKET BY TYPE

4.1 Leuprorelin
4.2 Triptorelin
4.3 Others

5. COMPANY PROFILES

5.1 Beijing Biote Pharmaceutical Co., Ltd.
5.2 Livzon Pharmaceutical Group Inc.
5.3 Takeda Pharmaceutical Company Limited

6. APPENDIX

6.1 About StrategyHelix
6.2 Disclaimer


More Publications